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The glial-cell-line-derived neurotrophic factor (GDNF) ligand activates the Ret receptor through the assembly of a multiprotein complex,
including the GDNF family receptor a1 (GFRa1) molecule. Given the neuroprotective role of GDNF, there is an obvious need to precisely
identify the structural regions engaged in direct interactions between the three molecules. Here, we combined a functional approach for Ret
activity (in PC12 cells) to cross-linking experiments followed by MS-MALDI to study the interactions among the purified extracellular
region of the human Ret, GDNF and GFRa1 molecules. This procedure allowed us to identify distinct regions of Ret that are physically
engaged in the interaction with GDNF and GFRa1. The lack of these regions in a recombinant Ret form results in the failure of both
structural and functional binding of Ret to GFRa1/GDNF complex. Furthermore, a model for the assembly of a transducing-competent Ret
complex is suggested.
D 2004 Elsevier Inc. All rights reserved.
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The ret protooncogene encodes a tyrosine kinase
receptor that plays a crucial role in kidney morphogenesis
and in the survival and differentiation of several subpopu-
lations of neurons in the peripheral and central nervous
systems [1]. The Ret protein consists of three functional0898-6568/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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cadherin-like domains (named CLD1 to CLD4) followed by
a single cysteine-rich domain (CRD), the transmembrane
region and the intracellular region formed by a bipartite
tyrosine kinase domain [2].
Four members of the glial cell line-derived neurotrophic
factor (GDNF) family, including GDNF, neurturin, artemin
and persephin represent the Ret ligands. Ret activation by
these neurotrophic factors is mediated by their binding to
one of the four different glycosyl phosphatidylinositol-
anchored receptors, termed GDNF family receptor a
(GFRa) 1 to 4 [3]. GDNF has potent trophic effects on
dopaminergic nigral neurons, indicating this factor as a
promising protective agent in neurodegenerative diseases.
In various animal models of Parkinson’s disease, GDNF
has been shown to prevent the neurotoxin-induced death(2005) 717–727
A. Amoresano et al. / Cellular Signalling 17 (2005) 717–727718of dopamine neurons and can promote functional recovery
(for a review, see Ref. [4]). Despite a cross-talk between
the different ligands–GFRas pairs, a preferred coreceptor
molecule exists for each ligand, GDNF being the preferred
high-affinity ligand for GFRa1. On the other hand, in the
absence of GFRa1, Ret is not able to bind GDNF,
whereas it can interact weakly with GFRa1 even in the
absence of GDNF [5–7]. GDNF-dependent activation of
Ret implicates its recruitment to the GFRa1/GDNF
complex, leading to Ret dimerisation and autophosphor-
ylation at specific cytoplasmic tyrosine residues [1].
Several structural elements in both GDNF and GFRa1
that are required for the formation of the complex have
been tentatively defined [8–10]. By constructing a set of
chimeric and truncated coreceptors and analysing their
ligand binding and signaling capabilities, a central domain
in the GFRa1 molecule was identified as necessary for
physical and biochemical interaction with both GDNF and
Ret molecules [11]. The crystal structure of the second
half of this central domain has been recently solved,
revealing it as an independent folding unit [12]. In
addition, homologue-scanning mutagenesis of GDNF
allowed identifying residues located along the second
finger of the ligand according to the crystal structure as
critical for the interaction with GFRas molecules [8,9]. On
the other hand, by constructing chimeric molecules
constituted by the human and the Xenopus regions of
the extracellular domain of Ret fused together, the binding
determinants for GFRa1/GDNF complex have been found
to be mainly concentrated in the first CLD1 of Ret [13].
However, the identification of regions and specific
residues directly engaged in the intermolecular interactions
among the Ret, GDNF and GFRa1 molecules and needed
to form a functionally active transducing complex is still
questioned.
This study is intended to identify key amino acids
engaged in direct interactions between the three molecules.
Nowadays, cross-linking reagents are widely used in the
assessment of contact regions in protein–protein interaction
mainly in combination with mass spectrometry as the
analytical methodology able to precisely identify covalently
linked residues [14–17].
Therefore, we used a proteomic-based approach to
study the interactions among the pure extracellular region
of human Ret, the GDNF and the GFRa1 molecules. The
three proteins were incubated in vitro and treated with a
limited excess of cross-linking reagents. The reaction
products were fractionated on SDS polyacrylamide gel
(SDS-PAGE), and the individual cross-linked species were
characterised by mass spectrometry fingerprinting analysis.
The obtained results led to the identification of distinct
regions in the extracellular region of Ret that are required
for the assembly of a transducing-competent three-compo-
nent complex. Signal transduction experiments in PC12
cells fully confirmed the structural analyses findings of the
used approach.2. Materials and methods
2.1. Cloning, expression and purification of EC-Ret proteins
The entire Ret receptor extracellular portion (EC-Retwt)
was produced as previously reported [18]. The protein
containing the first three N-terminal CLDs of EC-Retwt but
lacking CLD4 and CRD (named EC-Ret1–387) was produced
as follows.
A fragment encoding residues 1–387 of EC-Retwt was
amplified using Taq polymerase in standard PCR conditions
(F:5VAGTGTTTAAATTTAAGCTTGCGGCCG3V and
R:5VCACATTCAAATGTAGTAAGGATCCGC3V). The C-
terminus of the resulting PCR fragment was ligated to a
fragment containing a tobacco etch virus (TEV) protease
cleavage site followed by the two IgG binding domains of S.
aureus protein A into a pcDNA 3.1 (+) expression vector
(Invitrogen). The resulting plasmid was transiently trans-
fected in HEK 293T cells at 90% confluence plated on to six
15-cm plates using the Lipofectamine 2000 reagent (Invi-
trogen). The ultrafiltrated culture medium (15 ml final
volume) was loaded onto an IgG Sepharose 6 Fast Flow
column (Amersham-Pharmacia, 0.53 cm), and the sample
was eluted in the presence of TEV protease. The recovered
sample was fractionated onto a Superdex 200 High Load
column (Amersham-Pharmacia, 130 cm) connected to a
Fast Protein Liquid Chromatography (FPLC) system. The
total protein yield was approximately 500 ng/ml of culture
medium.
2.2. Cell culture, preparation of cell extracts and immuno-
blotting analysis
PC12/wt (PC12 cells stably transfected with human Retwt
receptor) and PC12-a1/wt (PC12 cells stably transfected
with both human Retwt receptor and GFRa1 coreceptor)
cells were grown as previously reported [19]. When
indicated, GDNF (Promega) or recombinant rat GFRa1/-
Fc chimera (R&D System) were added to the culture
medium.
Cells were washed twice in ice-cold PBS then lysed in
50 mM Tris–HCl, pH 8.0 buffer containing 150 mM NaCl,
1% Nonidet P-40, 2 Ag/ml aprotinin, 1 Ag/ml pepstatin, 2
Ag/ml leupeptin, 1 mM Na3VO4. The solution was
centrifuged at 16,000 g for 30 min at 4 8C, and the residue
was discarded. Protein concentration was determined by the
Bradford assay using bovine serum albumin as standard.
After SDS-PAGE, proteins were electroblotted to polyvi-
nylidene difluoride membranes (Millipore) and detected
with the indicated primary antibodies and peroxidase-
conjugated secondary antibodies using the enhanced chem-
iluminescence system (Amersham-Pharmacia). The primary
antibodies used were the following: anti-Ret (H-300) and
anti-ERK1 (C-16; Santa Cruz Biotechnology), anti-phos-
phoRet (Cell Signaling), anti-phospho44/42 MAP Kinase
monoclonal antibodies (E10; Cell Signaling). When indi-
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6.7, 0.1 M 2-mercaptoethanol, 2% SDS, for 30 min at 55
8C. The immunoblots shown are examples of at least three
independent experiments.
2.3. Neurite outgrowth bioassay
PC12-a1/wt cells were plated at equal density on 12-well
culture plate. To evaluate the effects of EC-Ret proteins on
cell differentiation, cells were incubated with 50 ng/ml
GDNF together with the appropriate protein at a final
concentration of 10 Ag/ml. At least 15 random fields were
photographed 24 h after GDNF stimulation by using a
phase-contrast light microscope, and 30 cells per frame were
counted and scored as having neurites or not. A neurite was
operationally defined as a process outgrowth that was long
more than twice the diameter of cell body.
2.4. Deglycosylation procedure
Treatment with peptide N-glycosidase F (PNGase F) or
endoglycosidase H (Endo H) was performed according to
the protocol supplied by the manufacturer (New England
Biolabs).
2.5. Chemical modifications
Cross-linking reactions were carried out in a total volume
of 80 Al of 10 mM sodium phosphate buffer, pH 7.5.
Recombinant GDNF, GFRa1 and EC-Retwt or EC-Ret1–387
were mixed in equimolar amount (2106 mol/l) and
incubated at 25 8C for 30 min. Following complex
formation, either suberic acid bis (3-sulpho-N-idroxysucci-
nimide ester) sodium salt (BS3) or 1-ethyl-3-(3-dimethyla-
mino propyl)-carbodiimide (EDAC) cross-linking reagents
(Sigma) were added to the mixture. Several preliminary
experiments were carried out to precisely determine the
optimal excess of chemical reagents. A molar excess of
1:2500 (mol/mol) for both reagents was eventually defined,
and the modification reactions were allowed to proceed at
25 8C for 3 h.
2.6. SDS-PAGE analysis and bin situQ digestion
Cross-linking reactions were terminated by quenching
the excess of reagents with 20 Al of gel loading buffer (Tris–
HCl 180 mM, 6% SDS, 30% Glycerol, Blu Bromophenol
0.03%, pH 6.8). Samples were heated at 100 8C for 5 min
and then separated by gel electrophoresis through a 7%
tricine SDS polyacrylamide gel. Proteins were detected by
silver staining, and positively stained protein bands were
excised from the gel and washed in deionised MilliQ grade
water (2 times, 10 min). The excised spots were destained
with 100 Al of destaining solution (30 mM K3Fe(CN)6, 100
mM Na2S2O3) and washed with 100 Al of 100 mM
ammonium bicarbonate buffer. After 5 min, an equalamount of acetonitrile was added. Protein samples were
reduced by incubation in 10 mM dithiothreitol (DTT) for 45
min at 56 8C. Reducing solution was removed by
acetonitrile wash, and free cysteines were alkylated by
treatment with 55 mM iodoacetamide for 30 min at room
temperature in the dark. The supernatant of the alkylating
solution was discarded, and the reaction was stopped by
washing gel pieces with ammonium bicarbonate buffer and
acetonitrile. Enzymatic digestion was carried out by
incubating gel pieces with 30 Al of a 1 ng/Al trypsin
solution in 10 mM ammonium bicarbonate at 4 8C for 2 h.
The excess of trypsin solution was then removed, and a new
aliquot of 10 mM ammonium bicarbonate was added;
samples were incubated for 18 h at 37 8C. A minimum
reaction volume was used to obtain the complete hydration
of the gel. Peptides were then extracted by washing the gel
particles with 0.1% TFA in 50% acetonitrile at room
temperature. Peptides were purified by using ZipTip Pipette
Tips following manufacturer protocol (Millipore Billerica,
USA).
2.7. MALDI-MS analyses
MALDI-TOF mass spectra were recorded using an
Applied Biosystem Voyager DE-PRO instrument. A 1-Al
aliquot of a mixture of analyte and matrix solution (alfa-
cyano-hydroxycinnamic acid 10 mg/ml in 66% ACN, 0.1%
TFA, in MilliQ water) was applied to the metallic sample
plate and dried down at room temperature. Mass calibration
was performed using external peptide standards. Raw data
were analysed using the computer software provided by the
manufacturer and reported as monoisotopic masses. The
accuracy of the mass determinations was always within 30
ppm. The percentage of noninterpreted signals was less than
10%.3. Results
3.1. Production of EC-Retwt and EC-Ret1387
To perform cross-linking experiments, we took
advantage of pure protein preparations corresponding to
the entire Ret extracellular region, protein ending at
amino acid 636 (EC-Retwt) [18], and of a deletion
mutant encompassing CLD1, two and three of the native
protein but lacking CLD4 and CRD (EC-Ret1–387). The
recombinant Ret truncated form was produced as
described in Materials and methods section and charac-
terised for its homogeneity. An aliquot of 30 Ag of purified
EC-Ret1–387 loaded onto a Superdex 200 (FPLC System)
gave rise to a symmetric chromatographic peak with an
apparent molecular mass of approximately 80 kDa, which
was compatible with a homogeneous preparation of the
protein in a correctly folded conformation. However, the
correct folding of EC-Ret1–387 was further tested by
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glycosylation of the extracellular domain of human Ret is
not required for ligand binding, but it is relevant for the
folding and the maturation of the protein [20,21]. We
analysed the sensitivity of both EC-Retwt and EC-Ret1–387
proteins to PNGase F and Endo H. It is well known in fact
that PNGase F removes the oligosaccharide chains from all
glycoproteins regardless of their folding state, whereas Endo
H deglycosilates misfolded proteins that are retained in ER.
EC-Ret1–387 was incubated with either PNGase F or Endo
H, and the reaction products were analysed by SDS-PAGE
(Fig. 1). The same experiments were also carried out on
native Ret for comparison. As shown in Fig. 1, the correct
folding and maturation state of purified EC-Ret1–387 were
confirmed by its sensitivity to PNGase F and resistance to
Endo H treatment. Comparable results were obtained with
the EC-Retwt preparation (Fig. 1).
3.2. CLD4 and CRD are required for binding of EC-Retwt to
GFRa1/GDNF
By using the EC-Retwt and the deletion mutant
EC-Ret1–387 proteins, we determined whether the extrac-
ellular domain of Ret retains in vitro the ability to form a
multiprotein complex with GDNF and GFRa1 molecules.
Equimolar amounts of recombinant GDNF, GFRa1 and EC-
Retwt (2 AM final concentration each) were incubated in
vitro in phosphate buffer and allowed to interact to obtain
complex formation. In agreement with the methods reported
in literature for the in vitro chemical cross-linking (see Ref.
[14] as representative reference), low concentrations of the
three protein components were chosen to avoid unspecific
protein–protein interactions. Moreover, preliminary experi-
ments were carried out to precisely determine the appro-
priate molar excess of reagents to limit the amount of cross-
linking bonds and to avoid an excess of undesired surface
labelling. As previously reported, in fact, a large number of
chemical cross-links might perturb the native conformation
of the complex, whereas modification of surface amino
acids might greatly complicate the interpretation of the mass
spectral data [15,16].Fig. 1. Deglycosylation analysis of EC-Ret proteins. (A) SDS-PAGE (10% acrylam
staining; molecular-mass standards are shown. (B) EC-Ret1–387 or EC-Retwt before
5, respectively) or Endo H (lane 3 or 6, respectively) immunoblotted with anti-RThe cross-linking agent BS3, a bifunctional reagent
linking amines to amines, thus selective for the N-terminal
amino group and lysine side chains, with a spacer arm of
11.4 2 [22], was then added to the complex. The reaction
was stopped by direct dilution with sample buffer, and the
modified samples were fractionated by SDS-PAGE as
shown in Fig. 2 (left panel, lanes 3–6). Isolated GFRa1
and EC-Retwt proteins were also loaded onto the gel as
specific electrophoresis mobility standards (lanes 2 and 7).
Similar experiments were carried out using the truncated
form of Ret, EC-Ret1–387 (lanes 8–10).
Fig. 2 shows that the cross-linking reactions resulted in
the production of covalently linked species that were named
1A, 1B, 1C and 1D according to their electrophoretic
mobility (lanes 3–6). When the truncated EC-Ret1–387 was
used in the experiments, only three protein bands, namely,
2A, 2B and 2C, were observed (lanes 8 and 9). No evidence
of a high molecular weight band corresponding to the 1D
species was observed in these samples.
The protein bands were excised from the gel, reduced,
alkylated and in situ digested with trypsin [23]. The
resulting peptide mixtures were analysed by MALDI-MS
following the mass fingerprinting procedure [15]. As an
example, Fig. 3 shows the partial MALDI mass spectrum of
the peptide mixture from band 1D, the specific complex
only formed in the presence of native Ret protein. The mass
spectral analysis revealed the occurrence of mass signals
corresponding to linear peptides originated from the GDNF,
GFRa1 and Ret sequences, thus indicating that this band
corresponds to a three-component covalent complex involv-
ing GDNF, GFRa1 and EC-Retwt. Moreover, a series of
signals were identified in the mass spectra that could not be
assigned to any linear peptide. These signals were not
detected in the mass mapping of isolated GDNF, GFRa1
and Ret carried out as reference and were then interpreted as
modified fragments. These modifications might have been
generated either by surface labelling, i.e., BS3 modification
of exposed residues or by intra- and/or intermolecular cross-
links. The assignments of these mass signals were then
performed on the basis of the mass values recorded in the
spectra and the specificity of the trypsin digest [24], takingide) of a pure sample of EC-Ret1–387 revealed by Coomassie Brilliant Blue
(lane 1 or 4, respectively) and following treatment with PNGase F (lane 2 or
et antibodies.
Fig. 2. Silver-stained SDS PAGE analysis of samples from BS3 and EDAC cross-linking experiments. The samples loaded on the gel are as follows: BS3 (left
panel), markers (lane 1); GFRa1 (lane 2); cross-linking reaction between EC-Retwt, GDNF and GFRa1 (lanes 3–6, shown in triplicate); EC-Retwt (lane 7);
cross-linking reaction between the truncated EC-Ret1–387, GDNF and GFRa1 (lanes 8–9, shown in duplicate); EC-Ret1–387 (lane 10). EDAC (right panel), EC-
Retwt (lane 1); cross-linking reaction between EC-Retwt, GDNF and GFRa1 (lanes 2–3, shown in duplicate); GFRa1 (lane 4).
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peptide. The mass searching of the modified peptides was
carried out with a mass tolerance of 30 ppm, thus leading
to univocal attributions of the signals, as summarised in
Table 1. As an example, the signal at m/z 1045.6 was
assigned to the GFRa1 peptide 89–95 carrying a cova-
lently linked BS3 moiety, while the signal at m/z 1320.6Fig. 3. Partial MALDI mass spectrum of the peptide digest from band 1D. Mass s
and GFRa1 sequences on the basis of their mass values. Tripsin autoproteolysisrevealed the occurrence of an intramolecular cross-link
involving the fragments 89–91 and 92–97 of the GFRa1
sequence. Following this procedure, a number of real
intramolecular covalent bonds linking the three proteins
were detected. The signal at m/z 1475.8 was assigned to
the covalent cross-link between the peptide 91–97 of
GFRa1, oxidized at level of Met93, with the GDNF 1–4ignals were assigned to the corresponding peptides within GDNF, EC-Retwt
peaks are marked with an asterisk.
Table 1
Mass values and corresponding fragments from the BS3 cross-linking experiment
Measured mass (m/z) Modified peptides Residues Theoretical mass (m/z) Found in band
1045.6 Ra1 89–95^BS3 (internal) Ra1 90 Ra1 94 1045.6 1D
1079.5 Ra1 89–91^Ra1 92–95(ox) Ra1 90 Ra1 94(95) 1079.5 1D
1320.6 Ra1 89–91^Ra1 92–97(ox) Ra1 90 Ra1 94(95) 1320.6 1A, 1B, 1C, 1D, 2A, 2B, 2C
1429.6 Ra1 92–97(ox)^Ra1 191–194 Ra1 94(95) Ra1 191 1429.6 1A, 1B, 1C, 1D, 2B
1446.8 Ra1 91–97(ox)^GDNF 28–31 Ra1 94(95) GDNF 29 1446.84 1D
1461.8 Ra1 89–95^GDNF 28–31 Ra1 94(90,95) GDNF 29 1461.8 1D
1475.8 Ra1 91–97(ox)^GDNF 1–4 Ra1 94(95) GDNF 1 1475.8 1D
1497.8 GDNF 1–4^GDNF 28–35 GDNF 1 GDNF 29 1497.8 1D
1699.8 Ra1 95–97^Ra1 39–47 Ra1 95 Ra1 45 1699.8 1D
2225.2 Ra1 191–197^GDNF 125–134 Ra1 191 GDNF 129 2225.1 1A, 1B, 1D, 2B, 2C
2916.3 Ra1 96–101^RET 601–617 Ra1 97 RET 603 2916.3 1D
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as originated by the peptide 191–197 of GFRa1 covalently
linked to the fragment 125–134 of GDNF, confirming that
coreceptor/ligand interaction occurred through these
regions of the two proteins. As a whole, a detailed
examination of the data demonstrated that the GFRa1
region 91–97 is in close contact with the N-terminal
portion of the GDNF molecule (region 1–31) via covalent
cross-links involving either Lys94 or Lys95 of GFRa1 and
the N-terminal amino group and Lys29 of GDNF. A
further cross-link between the coreceptor and the ligand
was established through Lys129 in the C-terminal portion
of GDNF and either Lys191 or 194 of GFRa1, as reported
in Table 1. Finally, a direct interaction between GFRa1
and EC-Retwt was established through a chemical linkage
joining Lys97 of the coreceptor and Lys603 of Ret, as
indicated by the signal at m/z 2916.3 involving the GFRa1
96–101 peptide and the EC-Retwt 601–617 fragment. It
should be emphasised that no direct chemical cross-links
between EC-Retwt and the GDNF ligand could be
identified in the analysis.
The MALDI mass spectral analyses of the peptide
mixtures from bands 1A, 1B and 1C occurring in the
presence of the native EC-Retwt form showed the presence
of signals corresponding to peptides generated from tryptic
hydrolysis of the GDNF and GFRa1 molecules. No mass
signals corresponding to Ret sequences were detected,
indicating that these bands corresponded to heterodimeric
complexes consisting of GDNF and GFRa1 proteins. The
occurrence of three bands consisting of the same two
proteins but showing different electrophoretic mobilities
was interpreted as due to the different stoichiometry of the
cross-linked complexes between GFRa1 and the GDNFTable 2
Mass values and corresponding fragments from the EDAC cross-linking experim
Measured mass (m/z) Cross-linked peptides
1872.0 GFRa1 91–95(ox)^GDNF 5–14
2726.2 GFRa1 92–97(ox)^EC-Retwt 478–494
3301.7 GFRa1 91–101(ox)^GDNF 13–29ligand. On the basis of their electrophoretic mobility
referred to a calibration curve, the band 1C was tentatively
attributed to a 2:2 GDNF/GFRa1 complex, whereas bands
1A and 1B were assigned to GDNF/GFRa1 complex with
one GFRa1 molecule and different GDNF composition.
As reported in Table 1, several mass signals were
detected in the spectra that corresponded to intermolecular
covalently linked peptides, confirming that the region 191–
197 of GFRa1 is directly joined to the C-terminal domain of
GDNF. Interestingly, no linkages involving the N-terminal
region of GDNF were detected.
Similar results were obtained in the analysis of the 2A,
2B and 2C bands that essentially confirmed the structural
data obtained on the interaction between the ligand and
the receptor occurring in the presence of the truncated
EC-Ret1–387.
The possible role of ionic interactions in the formation of
the complex was investigated by selecting the acidic
residues of the proteins for cross-linking formation. Follow-
ing incubation of equimolar amounts of GDNF, GFRa1 and
EC-Retwt, the protein carboxyl groups were activated by
EDAC and allowed to react with amino groups to form zero-
length intermolecular bonds [25]. The reaction mixture was
then fractionated by SDS-PAGE (Fig. 2, right panel), and
the protein bands were digested in situ. The triptic mixture
from 3A and 3B bands were analysed by MALDI-MS
following the procedure as described, revealing the presence
of linear peptides generated from enzymatic digestion of the
GDNF, GFRa1 and Ret proteins, thus indicating the
presence of a ternary complex. All the mass signals
occurring in the spectra were attributed as described above.
The analysis of the mass signals corresponding to cross-
linked peptides essentially confirmed previous cross-linkingent
Cross-linked residues Theoretical mass (m/z)
GFRa1 94(95) GDNF 13 1872.0
GFRa1 94(95) EC-Retwt 480 2726.3
GFRa1 94(95) GDNF 24 3301.7
Fig. 4. Effect of EC-Ret proteins on Ret-mediated signaling. (A) PC12/wt
cells (350,000 cells/6 cm plate) were starved for 4 h and then treated for 10
min with preincubated mixtures (5 ml final volume of RPMI medium),
including GDNF (1.6 nM), soluble GFRa1 (1.6 nM) and EC-Ret1–387 or
EC-Retwt at the indicated concentrations. Cell lysates were immunoblotted
with anti-phosphoRet antibodies (upper panel), the same filter was stripped
and hybridized with anti-Ret antibodies (lower panel). (B) Cell lysates from
cells treated as in panel (A) were immunoblotted with anti-phosphoERK
antibodies (upper panel); the same filter was stripped and hybridized with
anti-ERK antibodies (lower panel). (C) EC-Retwt and EC-Ret1–387 were
treated for 10 min at 37 8C in RPMI medium (2 Ag/ml final concentrations)
and then loaded onto a Superdex 200 High Load gel filtration column. The
molecular sizes of EC-Retwt and EC-Ret1–387 are indicated.
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portion is in close contact with the 91–97 region of the
receptor GFRa1, as demonstrated by the cross-links
between Glu13 and Glu24 of GDNF with either Lys94 or
95 from GFRa1. Moreover, a covalent linkage joining the
92–97 region of GFRa1 and Glu480 of Ret was identified,
thus further supporting the occurrence of a direct interaction
between EC-Retwt and the coreceptor. The mass finger-
printing analyses of the cross-linked bands corresponding to
the GDNF/GFRa1 complex essentially confirmed the
results obtained with BS3.
3.3. EC-Ret1–387 does not compete with membrane-bound
Retwt for binding to GDNF
To further confirm that the CLD4 and CRD are required
for binding to GFRa1/GDNF complex, we investigated
whether EC-Ret1–387 may act as a competitive inhibitor for
membrane-bound Ret. Indeed, as previously reported [18],
EC-Retwt inhibits the GDNF-induced Ret activity by com-
peting the membrane-bound Ret receptor for ligand binding.
We determined whether EC-Ret1–387 could interfere with the
GDNF-induced stimulation of Ret. We took advantage of a
PC12 derivative cell line expressing human Retwt (PC12/wt).
As shown in Fig. 4A, in the presence of soluble GFRa1,
GDNF stimulates Ret tyrosine phosphorylation (compare
lane 2 to lane 1). Treating cells with increasing amounts of
EC-Ret1–387 did not affect the Ret phosphorylation (compare
lanes 3 and 4 to lane 2), whereas EC-Retwt, used as a positive
control, greatly decreased Ret tyrosine phosphorylation level,
almost reaching the basal values (compare lanes 5 and 6 to
lane 2). Accordingly, phosphorylation of the Ret downstream
effector, ERK, was undetectable in the absence of the ligand
(Fig. 4B, lane 1) and strongly stimulated by GDNF in the
presence of soluble GFRa1 (lane 2), thus suggesting the
integrity of the signal transmission pathway. The truncated
EC-Ret1–387 was not able to inhibit the GDNF-induced ERK
phosphorylation (lanes 3 and 4), whereas, as expected, EC-
Retwt behaved as a potent inhibitor (lanes 5 and 6).
As an appropriate control, we verified that the 10-min
treatment of both EC-Retwt and EC-Ret1–387 at 37 8C in
RPMI medium at a final concentration of 2 Ag/ml did not
cause protein aggregation or misfolding of the proteins. The
elution profile from a Superdex 200 column of the treated
proteins (Fig 4C) gave rise to a symmetric chromatographic
peak, with an apparent molecular mass compatible with the
size of 120 and 80 kDa for EC-Retwt and EC-Ret1–387,
respectively, thus indicating the correct conformation state
of the molecules. The same results were obtained at a final
concentration of 4 Ag of protein/ml of culture medium (not
shown).
These findings indicate that the presence of CLD4 and
CRD in the extracellular region are needed to compete Ret
receptor for binding to GDNF.
We thus determined the biological effects of both EC-
Retwt and EC-Ret1–387 proteins on Ret-dependent celldifferentiation. To this aim, we measured the GDNF-
dependent neurite outgrowth in PC12-a1/wt cells that stably
express both human Ret and GFRa1. As shown in Fig. 5A
and B, cells extended long neuritic processes in response to
1-day exposure to GDNF (b) in comparison with the
nonstimulated control cells (a). Treatment of the cells with
EC-Retwt (c) but not with EC-Ret1–387 truncated protein (d)
significantly reduced the number and length of neurites. To
further monitor the cell differentiation, we determined the
extent of induction of VGF by GDNF stimulation.
Consistently with the phenotypical effects reported above,
Fig. 5. Effect of EC-Ret proteins on GDNF-induced differentiation of PC12-a1/wt cells. (A) Cells were left nonstimulated (a) or stimulated with GDNF alone
(b) or together with EC-Retwt or EC-Ret1–387 proteins (c and d, respectively). Following 24 h of GDNF treatment, the percentage of neurite outgrowth was
calculated. (B) The data were expressed as percentage of neurite-bearing cells/total cells counted. Each experiment was repeated a minimum of three times. (C)
Cell lysates were immunoblotted with anti-VGF and, to confirm equal loading, with anti-ERK antibodies as indicated. The fold values over control set to 1
(lane b) have been calculated using the NIH Image Program.
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protein, strongly inhibits the GDNF-dependent stimulation
of VGF expression (Fig. 5C).4. Discussion
Given the obvious difficulty to solve the 3D structure of
the Ret/GFRa1/GDNF ternary complex, a need of structural
and functional information is still required to identify the
regions engaged in the interactions within the complex. The
availability of soluble forms of Ret extracellular domains,
GDNF and GFRa1 molecules allowed us to directly study
the interactions among these components in vitro, using
highly homogeneous proteins. We performed cross-linking
experiments involving the purified human Ret extracellularportion together with the entire GDNF and GFRa1
molecules followed by MALDI mass spectrometry finger-
printing analyses to obtain a direct identification of the
chemical linkages joining Ret, the ligand and the coreceptor
molecules. In these experiments, we used two recombinant
Ret protein forms, the first corresponding to the entire Ret
receptor extracellular portion (EC-Retwt) and the other one
to the three first N-terminal domains (CLD1–3) of Ret (EC-
Ret1–387) lacking the CLD4 and CRD.
The results presented here show that, following cross-
linking experiments in the presence of EC-Retwt, formation
of a three-component complex occurred that involved Ret,
GDNF and GFRa1 molecules. The pattern of chemical
cross-links observed in the analysis of this complex is
reported in Fig. 6. On the contrary, formation of the three-
component complex could not be detected when the
Fig. 6. Schematic representation of covalent cross-links joining GDNF, EC-Retwt and GFRa1. Lines represent cross-linking bonds; dotted lines indicate that
cross-links occur only if EC-Retwt was present in the complex. Regions concerned by cross-links are indicated by the respective amino acids and are
underlined. Domains of GDNF and GFRa1 proteins are labeled accordingly to Refs. [9,10], respectively.
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in the experiments. Moreover, formation of two-component
complexes involving GDNF and GFRa1 interacting with
different stoichiometry was observed in the presence of both
native and truncated Ret forms. The panel of covalent
linkages found between the ligand and the coreceptor was
only slightly different as compared to that observed in the
three-component complex. Finally, no complexes between
Ret and GDNF or between Ret and GFRa1 could be
detected in our analysis.
On the other hand, the current model for GDNF signaling
proposes that direct binding of GFRa1 to GDNF is a
required event to stimulate Ret and that Ret binding to
GFRa1 increases the affinity of GFRa1 for GDNF [8].
Although the absence of complexes between Ret and GDNF
could not rule out any substantial physical contacts between
these proteins, the data are in good agreement with the need
of GFRa1 in the same complex to stimulate Ret activity [8].
Applying a similar logic, it is reasonable to assume either
that Ret may bind uniquely to GFRa1 following conforma-
tional changes taking place in the coreceptor upon binding
GDNF or, alternatively, that a two-component complex of
Ret with GFRa1 can take place but at a lower stability with
respect to the three-component complex involving Ret,
GDNF and GFRa1. In the latter case, it would mean that the
affinity of Ret for the preformed GFRa1/GDNF complex is
higher than that of Ret for GFRa1 or GDNF kept separately.
As recently reported, the central domain of GFRa1 is
necessary to dictate the ligand binding specificity and is
critical for GDNF-induced Ret activation [10–12]. In
agreement with the reported importance of this central
region of GFRa1 for ligand binding, we found that the
region 191–197 of GFRa1 is directly joined to GDNF.
Interestingly, this GFRa1 region interacts with the 125–134
region in the C-terminal domain of GDNF, which isneighbouring to a surface that includes four negatively
charged and four hydrophobic residues. The same region
has been reported to form a hot spot for GDNF binding to
the GFRa1 coreceptor [8]. Although GFRa1 binds the C-
terminal domain of GDNF both in the presence and in the
absence of Ret in the complex, an additional contact
between the 91–97 region of the GFRa1 molecule and the
N-terminal (1–31 residues) of the GDNF molecule occurs
exclusively if Ret is present in the same complex (see Fig.
6). This finding suggests that binding of Ret to GFRa1/
GDNF complex induces a conformational change in the
complex, causing the first residues of the N-terminal region
in the GDNF molecule to contact a newly exposed GFRa1
region encompassing residues 91–97. This model is well
supported by the assumption that the first 36 residues in the
N-terminus of GDNF represent a highly flexible region
since they could not be resolved in the crystal structure [26].
This large N-terminal region is well conserved between rat
and human, however, despite the high structural homology
with neurturin, artemin and persephin, it is unique to GDNF.
On the other hand, by transient expression assays, it has
been shown to be dispensable for stimulation of Ret
downstream signaling [9], thus raising the question of
understanding the function for this region in the complex. A
plausible interpretation for the results presented suggests
that this region could be implicated in the formation of a
high-affinity GDNF-binding site on GFRa1 that is observed
only in the presence of Ret [7].
The observation that a GFRa1 region (91–97), includ-
ing residues located in the third predicted a-helix of the N-
terminal domain, interacts with GDNF is in apparent
discrepancy with the dispensability of this region for
GDNF-induced stimulation of Ret. Indeed, variants of the
coreceptor molecule truncated of the entire N-terminal
domain still retain the ability to bind GDNF although at
A. Amoresano et al. / Cellular Signalling 17 (2005) 717–727726low efficiency, thus indicating that this region of GFRa1 is
not needed for ligand binding [11]. On the other hand,
cross-linking experiments with either of the specific
reagent used (BS3 and EDAC) strongly support the
relevance of this interaction. However, it should be pointed
out that the interaction of the N-terminal portion of
GFRa1 with the N-terminal region of GDNF only occurs
following formation of the ternary complex in the presence
of Ret. On the contrary, the contact between the GFRa1
191–197 region with the GDNF C-terminal portion was
observed regardless of the presence of Ret. Therefore, it is
reasonable to assume that the N-terminal portion of
GFRa1 is required to stabilize the GFRa1/GDNF com-
plex, thus explaining the suboptimal ligand binding
efficiency reported for the deletion mutants [11].
When the Ret, GDNF and GFRa1 three-component
complex was examined following cross-linking experi-
ments, we found that Ret is covalently linked to GFRa1,
but not to GDNF. In particular, the N-terminal portion of
GFRa1 joined to the CLD4 and CRD domains, located
proximal to the transmembrane domain, was involved in
these interactions. On the other hand, no interaction
involving the three first CLDs domains of Ret (CLD1–3)
was found with neither cross-linking reagents. Consistently,
we show that EC-Ret1–387 protein, corresponding to the
CLD1–3 domains and thus lacking both the CLD4 and
CRD, does not bind to GFRa1/GDNF complex since no
covalent cross-link involving EC-Ret1–387 was found. The
structural evidence that CLD4 and CRD are required for
binding of Ret to GFRa1/GDNF complex was strongly
confirmed by functional data on living cells. Indeed, in
PC12-a1/wt cells, the stimulation by GDNF of both Ret
intracellular signaling and cell differentiation were strongly
inhibited by EC-Retwt, but not by EC-Ret1–387 protein, thus
indicating that the truncated EC-Ret1–387 that lacks both
CLD4 and CRD is not able to act as inhibitory competitor
for the membrane-bound Ret receptor.
As a whole, these results demonstrate that CLD4 and
CRD are dispensable for the correct folding and maturation
of Ret extracellular domain, but they are necessary for both
structural and functional binding of Ret to the GFRa1/
GDNF complex.
By using the homologue-scanning mutagenesis analysis
between the extracellular domains of human and Xenopus
Ret, it has been reported [13] that the existence of a surface
spanning the three N-terminal CLDs (CLD1–3) of human
Ret that is required for ligand binding. This finding led to a
model that must presuppose a high flexibility of the Ret
extracellular portion, allowing Ret to reach the binding sites
on GFRa1 anchored to the plasma membrane. A strong
implication of our results resides in the possibility to
reformulate this interaction model, suggesting that require-
ment of CLD1–3 elements for binding is rather indirect,
while a physical interaction occurs between the C-terminal
portion of Ret (CRD and CLD4 domains) and the GFRa1/
GDNF complex in close contact with the cell membrane.The first three N-terminal domains of Ret either would
contribute to stabilize the complex once formed or might be
necessary for Ret to adopt a conformation competent for the
assembly of a functional complex.
In conclusion, we show that two small regions of GDNF
are engaged in close physical interactions with GFRa1, one
of which requires the presence of Ret in the same complex
to be positioned close to the GFRa1. Conversely, the
complex between Ret and GFRa1/GDNF is stabilized by
major contacts involving the N-terminal domain of GFRa1
and the CLD4 and the CRD domains of Ret. These domains
are necessary for both structural and functional binding of
the receptor to the complex. Results make it possible to
suggest a model for the molecular basis of ligand-mediated
Ret stimulation in attempts to design minimal agonists of
the GDNF molecule to be used both as therapeutics and
diagnostic agents for neurodegenerative diseases.Acknowledgments
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